Today: 19 July 2026
MongoDB stock drops nearly 5% to start 2026 as software sector lags; $400 level in focus
3 January 2026
1 min read

MongoDB stock drops nearly 5% to start 2026 as software sector lags; $400 level in focus

NEW YORK, Jan 3, 2026, 15:32 ET — Market closed

  • MongoDB ended Friday down 4.8% at $399.65 after swinging more than $39 intraday.
  • Software stocks lagged as Treasury yields climbed; the IGV software ETF fell 2.9%.
  • Traders are watching next week’s U.S. jobs data and MongoDB’s next earnings timing, expected in early March by third-party calendars.

MongoDB shares closed down 4.8% on Friday, sliding with high-growth software stocks in the first regular U.S. session of 2026. The database company ended at $399.65.

The pullback left the stock just under the $400 mark after it traded as low as $392.86 and as high as $432.70 in the session.

Why it matters now: investors started the year rotating into value shares as U.S. Treasury yields — government bond rates — moved higher. That shift often pressures richly valued software names because higher rates can compress valuations.

The iShares Expanded Tech-Software Sector ETF fell 2.9% on Friday, while the S&P 500 ETF edged up 0.2% and the Nasdaq-100 tracker QQQ slipped 0.2%, underscoring the split inside the market.

“Value is outperforming growth,” said Jed Ellerbroek, portfolio manager at Argent Capital in St. Louis.

Several software peers also finished lower. Snowflake fell 1.2% and Datadog dropped 1.6%, while larger database rival Oracle gained 0.4%.

Company-specific catalysts were limited. MongoDB on Friday posted a product update saying service accounts for Atlas Administration API access are now available in Atlas for Government. Service accounts are machine identities used to authenticate automated requests.

A Form 4 filing — an SEC disclosure of insider transactions — showed director Dev Ittycheria reported a gift of 13,039 shares dated Dec. 29.

The rate outlook stayed in focus into the weekend. Philadelphia Fed President Anna Paulson said further interest-rate cuts may take a while as the central bank gauges inflation and the labor market, comments that can weigh on rate-sensitive growth shares.

Before the next session on Monday, investors will parse a “spate” of employment indicators in the coming days after yields rose into Friday’s close. That data is viewed as a key input for the Federal Reserve’s policy path.

For MongoDB, attention is likely to shift back to fundamentals ahead of its next quarterly report. The company has not confirmed a date, but Zacks and MarketBeat calendars estimate results around March 4.

Traders are also looking toward the Federal Reserve’s next policy meeting, scheduled for Jan. 27-28, for signals on the pace of easing in 2026.

On charts, Friday’s close left $400 as a near-term line in the sand after the stock briefly dipped into the low $390s. A bounce would need to reclaim the low-$420s area — around Friday’s opening levels — to unwind the session’s drop.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • Neurocrine Biosciences (NBIX) Stock Fair Value and Performance in Focus
    July 19, 2026, 3:59 PM EDT. Neurocrine Biosciences (NBIX) is viewed as near fairly valued, with shares trading at a P/E ratio of 25.7x versus a fair value estimate of 26.0x. The stock has increased 73.4% over five years and posted a 29.4% gain in the past year, though this trails some competitors. Valuation signals are mixed, with about half indicating the stock could be expensive. Investors are assessing the resilience of cash flows from current therapies alongside operational risks. Growth prospects are supported by a broad pipeline, including late-stage assets and early commercial progress, yet policy changes and concentration risks are present. The overall assessment shows a valuation that reflects tempered expectations for Neurocrine's earnings potential and profitability.
UnitedHealth stock rises today as 2026 opens; UNH holds gains after hours with earnings ahead
Previous Story

UnitedHealth stock rises today as 2026 opens; UNH holds gains after hours with earnings ahead

Blackbaud stock slides nearly 6% to start 2026 as investors eye jobs data and mid-Feb earnings window
Next Story

Blackbaud stock slides nearly 6% to start 2026 as investors eye jobs data and mid-Feb earnings window

Go toTop